26,062 Shares in Natera, Inc. (NASDAQ:NTRA) Bought by Point72 DIFC Ltd

Point72 DIFC Ltd bought a new stake in Natera, Inc. (NASDAQ:NTRA) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 26,062 shares of the medical research company’s stock, valued at approximately $3,309,000.

Several other institutional investors have also modified their holdings of NTRA. Comerica Bank grew its position in Natera by 458.0% in the 1st quarter. Comerica Bank now owns 14,866 shares of the medical research company’s stock worth $1,360,000 after purchasing an additional 12,202 shares during the last quarter. Cetera Investment Advisers grew its holdings in Natera by 514.9% in the 1st quarter. Cetera Investment Advisers now owns 19,700 shares of the medical research company’s stock worth $1,802,000 after buying an additional 16,496 shares in the last quarter. Cetera Advisors LLC bought a new position in Natera in the 1st quarter worth approximately $442,000. DekaBank Deutsche Girozentrale acquired a new stake in Natera in the 1st quarter valued at approximately $83,000. Finally, GAMMA Investing LLC raised its stake in Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 108 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Insider Activity

In other Natera news, CEO Steven Leonard Chapman sold 4,728 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $146.41, for a total value of $692,226.48. Following the sale, the chief executive officer now directly owns 185,034 shares in the company, valued at $27,090,827.94. This trade represents a 2.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gail Boxer Marcus sold 9,682 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $159.98, for a total transaction of $1,548,926.36. Following the transaction, the director now directly owns 9,704 shares of the company’s stock, valued at $1,552,445.92. This represents a 49.94 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 46,503 shares of company stock valued at $6,325,804 over the last 90 days. 7.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of research analyst reports. StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. TD Cowen raised their target price on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners upped their price target on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Stephens reiterated an “overweight” rating and set a $125.00 price objective on shares of Natera in a research note on Friday, August 9th. Finally, Sanford C. Bernstein boosted their target price on Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $140.59.

Natera Trading Down 0.4 %

Natera stock opened at $169.17 on Wednesday. The stock has a market cap of $22.33 billion, a P/E ratio of -96.12 and a beta of 1.63. Natera, Inc. has a 12 month low of $55.56 and a 12 month high of $171.95. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company’s fifty day simple moving average is $137.36 and its 200-day simple moving average is $121.28.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company’s revenue was up 63.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.95) earnings per share. As a group, sell-side analysts forecast that Natera, Inc. will post -1.66 EPS for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.